Rapport Therapeutics, Inc. (RAPP)
Data as of , from SEC Form 4 filings.
See up to 3 months of RAPP. The 7-day demo opens the 1M and 3M ranges and puts RAPP on your watchlist.
Start 7-day demoLatest RAPP insider trades
About Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
- BOSTON, MA
- 84
- 2024
- XNAS
RAPP Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 21 | 148,136 | $6.95M |
RAPP insider transactions (Form 4)
6565 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Open-market sale | Common Stock | 3,552 | $29.05 footnote F2 | $103K | ||
| Open-market sale | Common Stock | 2,281 | $29.80 footnote F3 | $68K | ||
| Open-market sale | Common Stock | 2,983 | $29.04 footnote F4 | $87K | ||
| Open-market sale | Common Stock | 2,100 | $29.80 footnote F5 | $63K | ||
| ||||||
| David Bredt - Officer | Option exercise | Common Stock | 6,000 | $1.80 | $11K | |
| David Bredt - Officer | Option exercise | Stock Options (Right to Buy) | 6,000 | $0.00 | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 900 | $28.02 footnote F2 | $25K | |
| David Bredt - Officer | Open-market sale | Common Stock | 5,400 | $28.95 footnote F3 | $156K | |
| David Bredt - Officer | Open-market sale | Common Stock | 2,200 | $29.59 footnote F4 | $65K | |
| ||||||
| Jeffrey Sevigny - Officer | Grant or award | Stock Option (Right to Buy) | 130,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 428,000 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 148,000 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 120,000 | $0.00 | - | ||
| David Bredt - Officer | Grant or award | Stock Option (Right to Buy) | 103,000 | $0.00 | - | |
| Cheryl Gault - Officer | Grant or award | Stock Option (Right to Buy) | 132,000 | $0.00 | - | |
| Open-market sale | Common Stock | 5,833 | $26.12 footnote F2 | $152K | ||
| Open-market sale | Common Stock | 5,083 | $26.11 footnote F3 | $133K | ||
| ||||||
| David Bredt - Officer | Open-market sale | Common Stock | 8,300 | $26.83 footnote F2 | $223K | |
| David Bredt - Officer | Open-market sale | Common Stock | 200 | $27.40 | $5K | |
| ||||||
| David Bredt - Officer | Grant or award | Common Stock | 18,000 | - | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 6,567 | $30.05 | $197K | |
| Grant or award | Common Stock | 9,000 | - | - | ||
| Open-market sale | Common Stock | 2,840 | $30.05 | $85K | ||
| Open-market sale | Common Stock | 2,441 | $28.84 footnote F2 | $70K | ||
| Open-market sale | Common Stock | 2,792 | $30.04 footnote F3 | $84K | ||
| Open-market sale | Common Stock | 600 | $31.04 footnote F4 | $19K | ||
| Open-market sale | Common Stock | 2,147 | $28.84 footnote F5 | $62K | ||
| Open-market sale | Common Stock | 2,421 | $30.04 footnote F6 | $73K | ||
| Open-market sale | Common Stock | 515 | $31.04 footnote F7 | $16K | ||
| ||||||
| David Bredt - Officer | Open-market sale | Common Stock | 7,704 | $29.95 footnote F2 | $231K | |
| David Bredt - Officer | Open-market sale | Common Stock | 796 | $30.68 footnote F3 | $24K | |
| ||||||
| Cheryl Gault - Officer | Option exercise | Common Stock | 5,000 | $1.80 | $9K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 5,000 | $30.10 footnote F2 | $150K | |
| Cheryl Gault - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| ||||||
| David Bredt - Officer | Open-market sale | Common Stock | 5,344 | $25.39 footnote F3 | $136K | |
| David Bredt - Officer | Open-market sale | Common Stock | 3,156 | $24.84 footnote F2 | $78K | |
| ||||||
| Open-market sale | Common Stock | 2,777 | $24.92 footnote F2 | $69K | ||
| Open-market sale | Common Stock | 3,056 | $25.43 footnote F3 | $78K | ||
| Open-market sale | Common Stock | 2,242 | $24.91 footnote F4 | $56K | ||
| Open-market sale | Common Stock | 2,841 | $25.44 footnote F6 | $72K | ||
| ||||||
| David Bredt - Officer | Open-market sale | Common Stock | 7,418 | $25.73 footnote F2 | $191K | |
| David Bredt - Officer | Open-market sale | Common Stock | 1,082 | $26.16 footnote F3 | $28K | |
| ||||||
| Open-market sale | Common Stock | 4,647 | $25.72 footnote F2 | $120K | ||
| Open-market sale | Common Stock | 1,186 | $26.14 footnote F3 | $31K | ||
| Open-market sale | Common Stock | 4,328 | $25.75 footnote F4 | $111K | ||
| Open-market sale | Common Stock | 755 | $26.17 footnote F6 | $20K | ||
| ||||||
| Open-market sale | Common Stock | 39,435 | $26.30 | $1.04M | ||
| Open-market sale | Common Stock | 1,400 | $26.87 | $38K | ||
| Open-market sale | Common Stock | 34,885 | $26.30 | $918K | ||
| Open-market sale | Common Stock | 700 | $27.04 | $19K | ||
| Reid M. Huber | Open-market purchase | Common Stock | 20,400 | $24.48 | $499K | |
| Open-market purchase | Common Stock | 28,284 | $24.50 | $693K | ||
| Open-market purchase | Common Stock | 13,382 | $24.97 | $334K | ||
| David Bredt - Officer | Open-market sale | Common Stock | 5,098 | $23.88 | $122K | |
| David Bredt - Officer | Open-market sale | Common Stock | 3,402 | $24.66 | $84K | |
| Wendy B. Young | Open-market purchase | Common Stock | 3,500 | $22.60 | $79K | |
| Cheryl Gault - Officer | Option exercise | Common Stock | 5,000 | $1.80 | $9K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 5,000 | $38.33 | $192K | |
| Cheryl Gault - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 8,300 | $14.98 | $124K | |
| David Bredt - Officer | Open-market sale | Common Stock | 200 | $15.79 | $3K | |
| David Bredt - Officer | Open-market sale | Common Stock | 8,500 | $14.00 | $119K | |
| Robert J. Perez | Grant or award | Stock Option (Right to Buy) | 10,925 | $0.00 | - | |
| James Healy | Grant or award | Stock Option (Right to Buy) | 21,850 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 21,850 | $0.00 | - | ||
Recent RAPP Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Abraham N. Ceesay | Officer | 39,470 | $1.23M | View on EDGAR | |
| CHERYL GAULT | Officer | 10,000 |
RAPP insider trading FAQ
What is the latest insider trade for RAPP?
Rapport Therapeutics, Inc. (RAPP) had 9 insider filings in the last 90 days, with the most recent on 2026-10-08. The full record for RAPP runs to 65 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RAPP stock?
No insider purchases of RAPP were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling RAPP stock?
21 insider sales of RAPP were filed in the last 90 days, totaling $6.95M.
Where can I see RAPP SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RAPP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Abraham Ceesay view on EDGAR
- - Cheryl Gault view on EDGAR
- - Abraham Ceesay view on EDGAR
- - Abraham Ceesay view on EDGAR
- - Abraham Ceesay view on EDGAR
- - Krishnaswamy Yeleswaram view on EDGAR
- - Krishnaswamy Yeleswaram view on EDGAR
- - Abraham Ceesay view on EDGAR
- - Abraham Ceesay view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RAPP's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RAPP with a 7-day demo
- RAPP on your watchlist
- Every RAPP Form 4 filing on record
- Up to 3 months of RAPP price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive